13856/34347US=109 / Câncer
Salgia R, Blanco R, Skarin AT. Lung cancer and tumors of the heart and mediastinum. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 98-159. ISBN 978-0-323-05905-3.

CANCER DE PULMAO; TUMORES DO CORACAO; TUMORES DO MEDIASTINO

13857/34347US=9 / Urologia
Culig Z. 5-Alpha reductase inhibitors in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 83-9. ISBN 978-1-60327-831-7.

CANCER DE PROSTATA; 5-ALFA REDUTASE; DUTASTERIDE; FINASTERIDE; ISOENZIMA

13858/34347US=109 / Câncer
Janne PA, Wu D, Chirieac LR. Malignant mesothelioma. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 160-8. ISBN 978-0-323-05905-3.

MESOTELIOMA MALIGNO; MESOTELIOMA. APRESENTACAO CLINICA; MESOTELIOMA. DIAGNOSTICO; MESOTELIOMA. ESTADIAMENTO; MESOTELIOMA. FATORES PROGNOSTICOS; MESOTELIOMA. TRATAMENTO; CIRURGIA; QUIMIOTERAPIA; IRRADIACAO

13859/34347US=109 / Câncer
Meyerhardt JA, Kulke MH, Turner JR. Cancer of the gastrointestinal tract and neuroendocrine tumors. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 169-232. ISBN 978-0-323-05905-3.

CANCER DO TRATO GASTROINTESTINAL; TUMORES NEUROENDOCRINOS; CANCER ESOFAGICO; CANCER GASTRICO; CANCER PANCREATICO; CANCER HEPATOBILIAR; CANCER DE INTESTINO DELGADO; CANCER COLORRETAL; CANCER ANAL

13860/34347US=9 / Urologia
Friedlander TW, Ryan CJ. Adrenal androgen synthesis inhibitor therapies in castration-resistant prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 91-100. ISBN 978-1-60327-831-7.

SINTESE DE ANDROGENOS ADRENAIS; TERAPIAS INIBIDOR NA CASTRACAO-RESISTENTE; CANCER DE PROSTATA; TERAPIA HORMONAL SECUNDARIA; ANDROGENIOS ADRENAIS; ANDROGENO-INDEPENDENTES CANCER DE PROSTATA; CANCER DE PROSTATA HORMONIO REFRATARIO; FASE I; FASE I DE ENSAIOS CLINICOS; FARMACOCINETICA

13861/34347US=9 / Urologia
Sharifi N. Androgen deprivation therapy. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 101-7. ISBN 978-1-60327-831-7.

TERAPIA DE PRIVACAO DE ANDROGENO; TERAPIA DE PRIVACAO DE ANDROGENO; ANDROGENOS; CANCER DE PROSTATA; TESTOSTERONA

13862/34347US=9 / Urologia
Marques FZC, Reichardt JKV. Pharmacogenetics of the androgen metabolic pathway. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 109-21. ISBN 978-1-60327-831-7.

FARMACOGENETICA; ANDROGENOS; DOENCA MULTIFATORIAL; CANCER DE PROSTATA; CANCER DE PROSTATA. TRATRAMENTO; CANCER DE PROSTATA. PREVENCAO; CANCER DE PROSTATA. FARMACOGENETICA

13863/34347US=9 / Urologia
Halterman P, Vogelzang NJ, Farabishahadel A, Goodman Jr OB. Mitoxantrone. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 125-31. ISBN 978-1-60327-831-7.

MITOXANTRONA; DHAD; CANCER DE PROSTATA; CRPC; TERAPIA DE RESGATE

13864/34347US=9 / Urologia
Phillips CK, Petrylak DP. Docetaxel. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 133-46. ISBN 978-1-60327-831-7.

DOCETAXEL; QUIMIOTERAPIA; SOBREVIVENCIA; RESISTENTE A CASTRACAO CANCER DE PROSTATA

13865/34347US=9 / Urologia
Rosenberg J. Beyond Docetaxel: emerging agents in the treatment of advanced prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 147-51. ISBN 978-1-60327-831-7.

DOCETAXEL; CANCER DE PROSTATA AVANCADO; INIBICAO DE MTOR; NOVAS TERAPEUTICAS; DESACETILACAO DAS HISTONAS; HSP90; FATOR 1 DE CRESCIMENTO COM INSULINA

13866/34347US=9 / Urologia
Brick A, Niu J, Huang J, Oh WK. Platinum agents in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 153-61. ISBN 978-1-60327-831-7.

AGENTES DE PLATINA NO CANCER DE PROSTATA; CARBOPLATINA; NEUROENDOCRINO; RESISTENTE A CASTRACAO; QUIMIOTERAPIA

13867/34347US=9 / Urologia
Sissung TM, Figg WD. Clinical pharmacology and pharmacogenetics of chemotherapy in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 163-77. ISBN 978-1-60327-831-7.

FARMACOGENETICA DA QUIMIOTERAPIA. CANCER DE PROSTATA; FARMACOLOGIA CLINICA; DOCETAXEL; MITOXANTRONA; ESTRAMUSTINA; SATRAPLATIN; CANCER DE PROSTATA; FARMACOGENETICA; FARMACOLOGIA

13868/34347US=9 / Urologia
Fojo AT, Adelberg DE. Microtubule targeting agents. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 179-94. ISBN 978-1-60327-831-7.

CITOESQUELETO; MICROTUBULOS; TUBULINA; QUIMIOTERAPIA; CANCER DE PROSTATA

13869/34347US=109 / Câncer
Oh WK, Ross R, Choueiri TK, Kantoff PW, Corless C. Cancer of the genitourinary tract. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 233-77. ISBN 978-0-323-05905-3.

CANCER DO TRATO GENITURINARIO; CANCER DE PROSTATA; CANCER DE BEXIGA; CANCER DE RIM; CANCER TESTICULAR; CANCER DE PENIS

13870/34347US=9 / Urologia
Chau CH, Figg WD. Principles of antiangiogenic therapy. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 197-205. ISBN 978-1-60327-831-7.

TERAPIA ANTIANGIOGENICA; ANGIOGENESE; INTERRUPTOR ANGIOGENICO; INIBIDOR DA ANGIOGENESE; DENSIDADE MICROVASCULAR; ANTIANGIOGENICA TERAPIA

13871/34347US=109 / Câncer
Hirsch MS, Krag KJ, Matulonis UA. Gynecologic tumors and malignancies. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 278-324. ISBN 978-0-323-05905-3.

CANCER GINECOLOGICO; CARCINOMA DE OVARIO; CANCER ENDOMETRIAL; CANCER CERVICAL; CARCINOMA VULVAR; CARCINOMA VAGINAL; CARCINOMA TROMPA DE FALOPIO; CARCINOMA PERITONEAL; NEOPLASIA TROFOBLASTICA GESTACIONAL

13872/34347US=9 / Urologia
Elfiky AA, Kelly WK. Bevacizumab in advanced prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 207-14. ISBN 978-1-60327-831-7.

BEVACIZUMAB IN ADVANCED PROSTATE CANCER; ANGIOGENESE; CANCER DE PROSTATA; DROGAS; BEVACIZUMAB

13873/34347US=109 / Câncer
Chen WY, Campos SM, Hayes DF. Breast cancer. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 325-64. ISBN 978-0-323-05905-3.

CANCER DE MAMA; CANCER DE MAMA. INCIDENCIA; CANCER DE MAMA. HISTOLOGIA; CANCER DE MAMA. DIAGNOSTICO; CANCER DE MAMA. TRATAMENTO; CANCER DE MAMA METASTATICO

13874/34347US=9 / Urologia
Gardner ER, Di Lorenzo G, Figg WD. Thalidomide and analogs. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 215-23. ISBN 978-1-60327-831-7.

TALIDOMIDA; LENALIDOMIDA; ANGIOGENESE; CANCER DE PROSTATA; IMUNOMODULADORES

13875/34347US=109 / Câncer
Sadow PM, Socinski MA, Moore FD Jr. Endocrine neoplasia. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 365-402. ISBN 978-0-323-05905-3.

NEOPLASIA ENDOCRINA; CANCER DA GLANDULA TIREOIDE; TUMOR DA GLANDULA ADRENAL; FEOCROMOCITOMA; PARAGANGLIOMA; TUMOR DA GLANDULA PITUITARIA; TUMORES NEUROENDOCRINOS; TUMORES DE CELULAS DA ILHOTA; SINDROMES DE NEOPLASIAS ENDOCRINAS MULTIPLAS

Primeira | Anterior | Próxima | Última